Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 6/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25837813 | 0.83 | HTR2C (0.37) | CPB2HTR2CSLC6A4HTR2ACACNA1G | |
| SCHEMBL22901061 | 0.83 | HTR2C (0.37) | CPB2HTR2CSLC6A4HTR2ACACNA1G | |
| SCHEMBL22900754 | 0.79 | HTR2C (0.35) | CPB2HTR2CSLC6A4HTR2ACACNA1G | |
| SCHEMBL22900760 | 0.79 | L3MBTL1 (0.39) | — | |
| SCHEMBL22900856 | 0.77 | NAMPT (0.38) | CPB2 | |
| SCHEMBL23251854 | 0.73 | HTR2C (0.42) | HTR2CSLC6A4HTR2ACACNA1GCACNA1B | |
| SCHEMBL21528021 | 0.71 | TAAR1 (0.43) | HTR2CSLC6A4 | |
| SCHEMBL21528145 | 0.70 | POLB (0.45) | HTR2CSLC6A4 | |
| SCHEMBL1936823 | 0.70 | HTR2C (0.40) | HTR2CSLC6A4CACNA1GCACNA1BCACNA1C | |
| SCHEMBL16629765 | 0.68 | HTR2C (0.39) | HTR2CSLC6A4HTR2ACACNA1GCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691967-B2 | Antibiotics effective for gram-negative pathogens | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691967-B2 | Antibiotics effective for gram-negative pathogens | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210017165-A1 | ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-01-21 | — | — | US | disclosed |
| WO-2019177975-A1 | ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017165-A1 | ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS | PGLS, MGAM, GMDS | CPB2 3887/4885HTR2C 4462/4885SLC6A4 3639/4885 |
| US-11691967-B2 | Antibiotics effective for gram-negative pathogens | PGLS, MGAM, GMDS | CPB2 3887/4885HTR2C 4462/4885SLC6A4 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.